Neuphoria Therapeutics Files Definitive Proxy Materials

TL;DR

Neuphoria (NEPH) filed proxy docs, shareholders vote soon.

AI Summary

Neuphoria Therapeutics Inc. filed definitive additional materials on November 24, 2025, related to its proxy statement. The company, formerly known as Bionomics Limited/FI, is a pharmaceutical preparations company based in Burlington, MA. This filing is a definitive proxy statement, indicating it's for a shareholder meeting.

Why It Matters

This filing provides shareholders with crucial information for an upcoming meeting, impacting their voting decisions on company matters.

Risk Assessment

Risk Level: low — This filing is a standard proxy statement and does not contain new financial information or strategic changes that would inherently increase risk.

Key Players & Entities

• Neuphoria Therapeutics Inc. (company) — Registrant
• BIONOMICS LIMITED/FI (company) — Former company name
• November 24, 2025 (date) — Filing date

FAQ

Key Financial Figures

• $100 billion — at Rothschild, where he advised on over $100 billion of transactions across more than 40 dea

Filing Documents

• ea0266948-defa14a_neuphoria.htm (DEFA14A) — 35KB
• image_001.jpg (GRAPHIC) — 4KB
• 0001213900-25-114148.txt ( ) — 41KB

Forward-Looking Statements

Forward-Looking Statements Neuphoria cautions that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as “may,” “could,” “will,” “would,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “intend,” “predict,” “seek,” “contemplate,” “potential,” “continue” or “project” or the negative of these terms or other comparable terminology are intended to identify forward-looking statements. The forward-looking statements are based on our current beliefs, plans, burn rate and expectations. Certain forward-looking statements, including (without limitation) about (1) Neuphoria’s ability to develop and expand its business, successfully complete development of its current product candidates, the timing of commencement and/or completion, as well as any successful or other outcome of various clinical trials, and receipt of data and current and future collaborations for the development and commercialization of its product candidates, (2) the market for drugs to treat central nervous system diseases and pain conditions, and the Company’s ability to realize the commercial potential of its products, as well as its regulatory strategy related to its clinical trials and, if successful, the regulatory pathway to any next stage in development or commercialization, (3) Neuphoria’s financial resources, and capital allocation and corporate development strategy, (4) the Board’s review of strategic alternatives and evaluation of offers from third parties, and (5) assumptions underlying any such statements. The inclusion of forward-looking statements should not be regarded as a representation by Neuphoria that any of its plans will be achieved. Future events and actual result

View Full Filing

View this DEFA14A filing on SEC EDGAR